Assertion: bronchospasm | /r/RelatedTo | chronic bronchitis
Facets:
Source sentences:
text: The Spiriva HandiHaler (Boehringer Ingelheim/Pfizer) was approved in 2004 for the long-term maintenance treatment of bronchospasm associated with COPD, including chronic bronchitis and emphysema.
text: The Spiriva HandiHaler, marketed by Boehringer Ingelheim and Pfizer, was approved in 2004 for the long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
text: The dry-powder formulation of tiotropium, marketed as the Spiriva Handi-Haler by Boehringer Ingelheim and Pfizer, was approved in the United States in 2004 for long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disorder, including chronic bronchitis and emphysema.
text: Uses: Long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema; to reduce exacerbations in COPD patients
text: For maintenance treatment of bronchospasm associated with COPD (including chronic bronchitis and emphysema), the usual dosage for adults is 2 inhalations (42 mcg) twice daily (morning and evening, approximately 12 hours apart).
text: Atrovent HFA Inhalation Aerosol is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.